Needham & Company LLC Reaffirms Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They currently have a $10.00 price target on the stock.

A number of other analysts have also issued reports on AUTL. Truist Financial raised Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. HC Wainwright initiated coverage on Autolus Therapeutics in a research note on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, January 21st. Mizuho lowered their price objective on Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. Finally, Zacks Research raised Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $8.50.

Autolus Therapeutics Price Performance

Shares of NASDAQ:AUTL opened at $1.49 on Thursday. The business’s 50 day moving average price is $1.48 and its 200-day moving average price is $1.52. The firm has a market capitalization of $396.55 million, a PE ratio of -1.38 and a beta of 2.04. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Friday, March 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.07). The firm had revenue of $24.29 million during the quarter, compared to analyst estimates of $23.92 million. Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%. As a group, analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marex Group plc acquired a new position in Autolus Therapeutics during the second quarter worth $28,000. Independent Advisor Alliance purchased a new stake in Autolus Therapeutics in the fourth quarter valued at $28,000. SmartHarvest Portfolios LLC purchased a new stake in Autolus Therapeutics in the fourth quarter valued at $43,000. Caitong International Asset Management Co. Ltd purchased a new stake in Autolus Therapeutics in the third quarter valued at $46,000. Finally, R Squared Ltd raised its position in Autolus Therapeutics by 40.1% in the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock valued at $50,000 after purchasing an additional 8,730 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.